A detailed history of Bank Of America Corp transactions in Kronos Bio, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 3,533 shares of KRON stock, worth $3,356. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,533
Previous 6,123 42.3%
Holding current value
$3,356
Previous $7,000 57.14%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.92 - $1.5 $2,382 - $3,885
-2,590 Reduced 42.3%
3,533 $3,000
Q2 2024

Aug 14, 2024

BUY
$0.73 - $1.38 $276 - $523
379 Added 6.6%
6,123 $7,000
Q1 2024

May 15, 2024

SELL
$1.02 - $1.3 $29 - $37
-29 Reduced 0.5%
5,744 $7,000
Q4 2023

Feb 14, 2024

BUY
$0.75 - $1.49 $21 - $43
29 Added 0.5%
5,773 $7,000
Q2 2023

Aug 14, 2023

SELL
$1.24 - $1.92 $50,102 - $77,577
-40,405 Reduced 87.55%
5,744 $9,000
Q1 2023

May 12, 2023

BUY
$1.34 - $2.62 $10,418 - $20,370
7,775 Added 20.26%
46,149 $67,000
Q4 2022

Feb 10, 2023

BUY
$1.44 - $3.44 $28,041 - $66,987
19,473 Added 103.03%
38,374 $62,000
Q3 2022

Nov 14, 2022

BUY
$3.35 - $5.55 $8,994 - $14,901
2,685 Added 16.56%
18,901 $63,000
Q2 2022

Aug 12, 2022

SELL
$3.12 - $7.52 $442,004 - $1.07 Million
-141,668 Reduced 89.73%
16,216 $59,000
Q1 2022

May 16, 2022

BUY
$6.26 - $14.42 $827,859 - $1.91 Million
132,246 Added 515.82%
157,884 $1.14 Million
Q4 2021

Feb 08, 2022

BUY
$11.35 - $21.18 $145,211 - $270,976
12,794 Added 99.61%
25,638 $349,000
Q3 2021

Nov 15, 2021

SELL
$18.17 - $24.7 $72,243 - $98,207
-3,976 Reduced 23.64%
12,844 $269,000
Q2 2021

Sep 13, 2021

BUY
$20.08 - $29.02 $337,745 - $488,116
16,820 New
16,820 $402,000

Others Institutions Holding KRON

About Kronos Bio, Inc.


  • Ticker KRON
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,769,100
  • Market Cap $53.9M
  • Description
  • Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...
More about KRON
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.